Insurers testing exotics for Solvency II optimisation

Dealers tackle uncertainty over basis risk

Exotic strategies are tempting insurers

With just weeks to go until Solvency II comes into force at the start of 2016, European insurers have been turning to complex equity derivatives in a bid to manage their capital more efficiently. But with continuing uncertainty surrounding some of the finer details of the regulation and a lack of clarity over exactly what constitutes excessive basis risk, both dealers and insurers have to make some educated guesses about what will qualify for capital relief.

"There is always going to be a suite

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here:

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: